In March 2019 Secura Bio acquired the global rights of Farydak from Novartis, and announced that Inceptua is appointed as distributor for Farydak in the Nordic region.
Farydak (panobinostat) is a prescription oral medication used in combination with proteasome inhibitors and corticosteroids to treat patients with relapsed or refractory multiple myeloma who have received prior treatments.
Please always consult local prescribing information and labelling text before use.
For more information about Farydak please refer to the prescribing information: European Medicines Agency.
Health Care Professionals and Adverse Event Report Privacy Notice.
Inceptua Pharma Medicines Access Policy
If you would like to speak to a medical representative, please use the relevant local/regional phone number below or contact:
Safety and adverse events
Patient safety is a key priority for us. For any suspected adverse drug reactions associated with Farydak supplied by Inceptua, please contact:
Telephone: +1-978-435-6968 / Fax: +1-858-925-6211